Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026)
Xilio Therapeutics' (XLO) quarterly Asset Utilization Ratio came in at 0.4 in Q2 2026, up 219.39% year-over-year from 0.13 in Q2 2025, and up 20.0% quarter-over-quarter from 0.34 in Q1 2026.
Powered by 
Analysis
Xilio Therapeutics (XLO) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Xilio Therapeutics has disclosed Asset Utilization Ratio across 2 years of filings, most recently posting 0.4 for Q2 2026.
- In Q2 2026, Asset Utilization Ratio rose 219.39% year-over-year to 0.4; the TTM figure through Jun 2026 stood at 0.4 (up 219.39% YoY), while the FY2025 annual figure was 0.39, up 303.37% from the prior year.
- Asset Utilization Ratio came in at 0.4 for Q2 2026 at Xilio Therapeutics, up from 0.34 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.4 in Q2 2026 to a low of 0.11 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.38 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 0.20 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 0.00 |
| 10 | Xilio Therapeutics | 174.55 Mn | 38.51 Mn | - | 0.40 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.40 |
| Mar 31, 2026 | 0.34 |
| Dec 31, 2025 | 0.30 |
| Sep 30, 2025 | 0.24 |
| Jun 30, 2025 | 0.13 |
| Mar 31, 2025 | 0.11 |